Qualitative Change in Migraine Prevention?

Roger Cady, Richard B. Lipton

Research output: Contribution to journalArticlepeer-review

7 Scopus citations


A new generation of drugs that target calcitonin gene-related peptide (CGRP) pathways offers a unique opportunity to explore the relationship between responder rates (RRs) and improvement in patient outcomes. The authors hypothesize a “tipping point” exists for patients with a ≥75% migraine response. They propose higher RRs reported in trials with CGRP inhibitory antibodies deliver not only a quantitative change in monthly headache days, but also a qualitative change in function, for a clinically meaningful subpopulation of patients.

Original languageEnglish (US)
Pages (from-to)1092-1095
Number of pages4
Issue number7
StatePublished - Jul 1 2018

ASJC Scopus subject areas

  • Neurology
  • Clinical Neurology


Dive into the research topics of 'Qualitative Change in Migraine Prevention?'. Together they form a unique fingerprint.

Cite this